# Resource Summary Report

Generated by RRID on Aug 24, 2026

## pcDNA3-sACE2(WT)-8his

RRID:Addgene_149268
Type: Plasmid

### Proper Citation

RRID:Addgene_149268

### Plasmid Information

**URL:** http://www.addgene.org/149268

**Proper Citation:** RRID:Addgene_149268

**Insert Name:** Angiotensin-converting enzyme 2

**Organism:** Homo sapiens

**Bacterial Resistance:** Ampicillin

**Defining Citation:** PMID:32753553

**Vector Backbone Description:** Backbone Marker:Invitrogen; Backbone Size:5332; Vector Backbone:pcDNA3.1(+); Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

**Comments:** Please visit https://www.biorxiv.org/content/10.1101/2020.03.16.994236v1 for BioRxiv preprint.

**Plasmid Name:** pcDNA3-sACE2(WT)-8his

**Relevant Mutation:** Extracellular, soluble protease domain (a.a. M1-D615)

**Record Creation Time:** 20220422T221828+0000

**Record Last Update:** 20260815T080713+0000

### Ratings and Alerts

No rating or validation information has been found for pcDNA3-sACE2(WT)-8his.

No alerts have been found for pcDNA3-sACE2(WT)-8his.

### Data and Source Information

**Source:** Addgene

## Usage and Citation Metrics

We found 11 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .


Idrovo-Hidalgo T, et al. (2024) Deglycosylated RBD produced in Pichia pastoris as a low-cost sera COVID-19 diagnosis tool and a vaccine candidate. Glycobiology, 34(1).

Berman K, et al. (2024) Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots. Microbiology spectrum, 12(12), e0084624.

Eliadis P, et al. (2024) Novel Competitive ELISA Utilizing Trimeric Spike Protein of SARS-CoV-2, Could Identify More Than RBD-RBM Specific Neutralizing Antibodies in Hybrid Sera. Vaccines, 12(8).

Rubio AA, et al. (2024) Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern. bioRxiv : the preprint server for biology.

Chen C, et al. (2023) hACE2-Induced Allosteric Activation in SARS-CoV versus SARS-CoV-2 Spike Assemblies Revealed by Structural Dynamics. ACS infectious diseases, 9(6), 1180.

Sergeeva AP, et al. (2023) Free Energy Perturbation Calculations of Mutation Effects on SARS-CoV-2 RBD::ACE2 Binding Affinity. Journal of molecular biology, 435(15), 168187.

Taha Z, et al. (2022) Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen. Molecular therapy : the journal of the American Society of Gene Therapy, 30(9), 2998.

, et al. (2022) Covalent coupling of Spike's receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2. Scientific reports, 12(1), 692.

Zhang L, et al. (2022) An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2. bioRxiv : the preprint server for biology.

Zhang L, et al. (2021) Engineered High-Affinity ACE2 Peptide Mitigates ARDS and Death Induced by Multiple SARS-CoV-2 Variants. bioRxiv : the preprint server for biology.

Procko E, et al. (2020) The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2. bioRxiv : the preprint server for biology.